文献速递泌尿生殖腹部MR

放射科医生对前列腺MRI检测临床显著前列腺癌变异性的贡献

Radiologists' Contribution to Variation in Detecting Clinically Significant Prostate Cancer in Men With Prostate MRI.
PubMed 文献 · J Am Coll Radiol · 2022-10-13

该回顾性队列研究纳入960例因PSA升高行mpMRI的男性,评估放射科医生对临床显著前列腺癌(csPCa)检出变异性的贡献。多因素分析显示,解读放射科医生个体因素(单独或联合其他医生)与csPCa检出无显著关联,而PI-RADS评分、PSA密度、保险类型和包膜外侵犯是独立预测因素。

要点

  • 放射科医生个体因素对csPCa检出变异无显著贡献。
  • PI-RADS 4和5类病灶与csPCa风险独立相关(OR分别为2.52和4.99)。
  • PSA密度≥0.1 ng/mL/cc及包膜外侵犯明确者csPCa风险增高。

关键影像表现/征象

  • mpMRI上明确包膜外侵犯与csPCa独立相关(OR 2.94,P = .01)。
  • PI-RADS 2类病灶与无局灶病变相比csPCa风险降低(OR 0.18,P = .04),PI-RADS 4类(OR 2.52,P < .001)和5类(OR 4.99,P < .001)风险增高。

诊断标准与关键数值

  • PI-RADS 2类 vs 无局灶病变:OR 0.18(P = .04);PI-RADS 4类:OR 2.52(P < .001);PI-RADS 5类:OR 4.99(P < .001)。
  • PSA密度0.1-0.15 ng/mL/cc:OR 2.46(P < .001);0.15-0.2 ng/mL/cc:OR 2.77(P < .001);≥0.2 ng/mL/cc:OR 4.52(P < .001)。
  • 私人保险 vs Medicare:OR 0.52(P = .001);包膜外侵犯明确:OR 2.94(P = .01)。

临床应用与阅片要点

  • 报告时应准确分配PI-RADS类别,尤其注意4类和5类病灶的识别。
  • 结合PSA密度等临床参数综合评估csPCa风险。
  • 明确报告包膜外侵犯等关键征象,辅助风险分层。

局限性

  • 单中心回顾性研究,结论外推需谨慎。
  • 未报告放射科医生间一致性的具体数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Assess radiologists' contribution to variation in clinically significant prostate cancer (csPCa) detection in patients with elevated prostate-specific antigen (PSA) and multiparametric MRI (mpMRI).

METHODS: This institutional review board-approved, retrospective cohort study was performed at a tertiary, academic, National Cancer Institute-designated Comprehensive Cancer Center with a multidisciplinary prostate cancer program. Men undergoing mpMRI examinations from January 1, 2015, to December 31, 2019, with elevated PSA (≥4 ng/mL) and biopsy within 6 months pre- or post-MRI or prostatectomy within 6 months post-mpMRI were included. Univariate and multivariable hierarchical logistic regression assessed impact of patient, provider, mpMRI examination, mpMRI report, and pathology factors on the diagnosis of Grade Group ≥ 2 csPCa.

RESULTS: Study cohort included 960 MRIs in 928 men, mean age 64.0 years (SD ± 7.4), and 59.8% (555 of 928) had csPCa. Interpreting radiologist was not significant individually (P > .999) or combined with mpMRI ordering physician and physician performing biopsy or prostatectomy (P = .41). Prostate Imaging Reporting and Data System (PI-RADS) category 2 (odds ratio [OR] 0.18, P = .04), PI-RADS category 4 (OR 2.52, P < .001), and PI-RADS category 5 (OR 4.99, P < .001) assessment compared with no focal lesion; PSA density of 0.1 to 0.15 ng/mL/cc (OR 2.46, P < .001), 0.15 to 0.2 ng/mL/cc (OR 2.77, P < .001), or ≥0.2 ng/mL/cc (OR 4.52, P < .001); private insurance (reference = Medicare, OR 0.52, P = .001), and unambiguous extraprostatic extension on mpMRI (OR 2.94, P = .01) were independently associated with csPCa. PI-RADS 3 assessment (OR 1.18, P = .56), age (OR 0.99, P = .39), and African American race (OR 0.90, P = .75) were not.

DISCUSSION: Although there is known in-practice variation in radiologists' interpretation of mpMRI, in our multidisciplinary prostate cancer program we found no significant radiologist-attributable variation in csPCa detection.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Naik, Burk, Budiawan, et al. Radiologists' Contribution to Variation in Detecting Clinically Significant Prostate Cancer in Men With Prostate MRI. J Am Coll Radiol. 2022. PMID: 36244674. doi:10.1016/j.jacr.2022.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。